Senseonics Holdings Inc

SENS

Market cap $338M

Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes

The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes

Senseonics (SENS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Senseonics stock jumps after Eversense 365 wins CE Mark, expanding Europe access for its one-year CGM and strengthening the long-term growth outlook.

GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced CE Mark approval for the Eversense® 365 CGM system.

Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.

twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM twiist™ becomes the first AID system compatible with Senseonics Eversense® 365 one-year CGM

Senseonics Holdings earns a buy rating as Eversense 365 drives potential product-market fit and margin expansion. SENS's integration of Ascensia's commercial team and DTC investments is expected to boost revenue and gross margins above 50%. Q3 revenue grew 90% YoY, with a 42.8% gross margin and 55% YoY revenue growth guided for 2025.